Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents
نویسندگان
چکیده
منابع مشابه
Mechanistic basis for overcoming platinum resistance using copper chelating agents.
Platinum-based antitumor agents are widely used in cancer chemotherapy. Drug resistance is a major obstacle to the successful use of these agents because once drug resistance develops, other effective treatment options are limited. Recently, we conducted a clinical trial using a copper-lowering agent to overcome platinum drug resistance in ovarian cancer patients and the preliminary results are...
متن کاملOvercoming platinum resistance through the use of a copper-lowering agent.
Low levels of human copper transporter 1 (hCtr1) mRNA are associated with a shorter progression-free survival after platinum-based therapy. Pretreatment with a copper-lowering agent such as trientine enhanced hCtr1-mediated platinum uptake. Therefore, we conducted a pilot study (NCT01178112) of carboplatin and trientine with the goal of resensitizing patients with advanced cancer to platinum ch...
متن کاملRecovery of copper and chelating agents from sludge extracting solutions
Recovery of copper and chelating agents from sludge extracting solutions Fang-Chih Chang a, Shang-Lien Lo a,∗, Chun-Han Ko b a Research Center for Environmental Pollution Prevention and Control Technology, Graduate Institute of Environmental Engineering, National Taiwan University, 71 Chou-Shan Road, Taipei 106, Taiwan, ROC b School of Forestry and Resource Conservation, National Taiwan Univers...
متن کاملNovel agents and strategies for overcoming EGFR TKIs resistance
Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target, EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR mutations, which has been a major breakthrough for lung cancer treatment.. The progression-free survival (PFS) of patients with EGFR mutations treated with EGFR TKIs is significantly prolonged compared with that of pati...
متن کاملOvercoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.
The nearly ubiquitous development of chemoresistant disease remains a major obstacle against improving outcomes for patients with ovarian cancer. In this investigation, we evaluated the preclinical activity of MLN4924, an investigational inhibitor of the NEDD8-activating enzyme, in ovarian cancer cells. Efficacy of MLN4924 both alone and in combination with platinum was assessed. Overall, singl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Molecular Cancer Therapeutics
سال: 2012
ISSN: 1535-7163,1538-8514
DOI: 10.1158/1535-7163.mct-12-0580